APA

Pott C., Sehn L. H., Belada D., Gribben J., Hoster E., Kahl B., Kehden B., Nicolas-Virelizier E., Spielewoy N., Fingerle-Rowson G., Harbron C., Mundt K., Wassner-Fritsch E. & Cheson B. D. (20200804). MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial. : Leukemia.

Chicago

Pott Christiane, Sehn Laurie H, Belada David, Gribben John, Hoster Eva, Kahl Brad, Kehden Britta, Nicolas-Virelizier Emmanuelle, Spielewoy Nathalie, Fingerle-Rowson Guenter, Harbron Chris, Mundt Kirsten, Wassner-Fritsch Elisabeth and Cheson Bruce D. 20200804. MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial. : Leukemia.

Harvard

Pott C., Sehn L. H., Belada D., Gribben J., Hoster E., Kahl B., Kehden B., Nicolas-Virelizier E., Spielewoy N., Fingerle-Rowson G., Harbron C., Mundt K., Wassner-Fritsch E. and Cheson B. D. (20200804). MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial. : Leukemia.

MLA

Pott Christiane, Sehn Laurie H, Belada David, Gribben John, Hoster Eva, Kahl Brad, Kehden Britta, Nicolas-Virelizier Emmanuelle, Spielewoy Nathalie, Fingerle-Rowson Guenter, Harbron Chris, Mundt Kirsten, Wassner-Fritsch Elisabeth and Cheson Bruce D. MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial. : Leukemia. 20200804.